Mia Husić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mia Husić has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Arun K. Ramani
Centre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
3 shared publications - Michael Brudno
University of Toronto
3 shared publications - Cynthia Hawkins
Division of Pathology, The Hospital for Sick Children, Toronto, Canada
2 shared publications - Michael Apostolides
Trauma & Orthopaedics Department, East Sussex Healthcare NHS Trust, Hastings, TN37 7PT, United Kingdom
2 shared publications - Robert Siddaway
Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
2 shared publications Yue Jiang
Centre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
2 shared publications
Latest Publications
- Open Access
MetaFusion: A high-confidence metacaller for filtering and prioritizing RNA-seq gene fusion candidates
Motivation Gene fusions are often associated with cancer, yet current fusion detection tools vary in their calling approaches, making selecting the right tool challenging. Ensemble fusion calling techniques appear promising; however, current options have limited accessibility and function. Results MetaFusion is a flexible meta-calling tool that amalgamates the outputs from any number of fusion callers. Results from individual callers are converted into Common Fusion Format, a new file type that standardizes outputs from callers. Calls are then annotated, merged using graph clustering, filtered and ranked to provide a final output of high confidence candidates. MetaFusion consistently outperformed individual callers with respect to recall and precision on real and simulated datasets, achieving up to 100% precision. Thus, an ensemble calling approach is imperative for high confidence results. MetaFusion also labels fusions found in databases using the FusionAnnotator package, and is provided with a benchmarking toolkit to calibrate new callers. Availability MetaFusion is freely available at https://github.com/ccmbioinfo/MetaFusion Contact arun.ramani{at}sickkids.ca
Open AccessMetaFusion: A high-confidence metacaller for filtering and prioritizing RNA-seq gene fusion candidates
Motivation Gene fusions are often associated with cancer, yet current fusion detection tools vary in their calling approaches, making selecting the right tool challenging. Ensemble fusion calling techniques appear promising; however, current options have limited accessibility and function. Results MetaFusion is a flexible meta-calling tool that amalgamates the outputs from any number of fusion callers. Results from individual callers are converted into Common Fusion Format, a new file type that standardizes outputs from callers. Calls are then annotated, merged using graph clustering, filtered and ranked to provide a final output of high confidence candidates. MetaFusion consistently outperformed individual callers with respect to recall and precision on real and simulated datasets, achieving up to 100% precision. Thus, an ensemble calling approach is imperative for high confidence results. MetaFusion also labels fusions found in databases using the FusionAnnotator package, and is provided with a benchmarking toolkit to calibrate new callers. Availability MetaFusion is freely available at https://github.com/ccmbioinfo/MetaFusion Contact arun.ramani{at}sickkids.ca
- Open Access
CReSCENT: CanceR Single Cell ExpressioN Toolkit
CReSCENT: CanceR Single Cell ExpressioN Toolkit ( https://crescent.cloud ), is an intuitive and scalable web portal incorporating a containerized pipeline execution engine for standardized analysis of single-cell RNA sequencing (scRNA-seq) data. While scRNA-seq data for tumour specimens are readily generated, subsequent analysis requires high-performance computing infrastructure and user expertise to build analysis pipelines and tailor interpretation for cancer biology. CReSCENT uses public data sets and preconfigured pipelines that are accessible to computational biology non-experts and are user-editable to allow optimization, comparison, and reanalysis for specific experiments. Users can also upload their own scRNA-seq data for analysis and results can be kept private or shared with other users.
Open AccessCReSCENT: CanceR Single Cell ExpressioN Toolkit
CReSCENT: CanceR Single Cell ExpressioN Toolkit ( https://crescent.cloud ), is an intuitive and scalable web portal incorporating a containerized pipeline execution engine for standardized analysis of single-cell RNA sequencing (scRNA-seq) data. While scRNA-seq data for tumour specimens are readily generated, subsequent analysis requires high-performance computing infrastructure and user expertise to build analysis pipelines and tailor interpretation for cancer biology. CReSCENT uses public data sets and preconfigured pipelines that are accessible to computational biology non-experts and are user-editable to allow optimization, comparison, and reanalysis for specific experiments. Users can also upload their own scRNA-seq data for analysis and results can be kept private or shared with other users.
- Open Access
Found in Transcription: Gene fusions arise through defects in RNA processing in the absence of chromosomal rearrangements
Recent advancements in high throughput sequencing analysis have enabled the characterization of cancer-driving fusions, improving our understanding of cancer development. Most fusion calling methods, however, examine either RNA or DNA information alone and are limited to a rigid definition of what constitutes a fusion. For this study we developed a pipeline that incorporates several fusion calling methods and considers both RNA and DNA to capture a more complete representation of the tumour fusion landscape. Interestingly, most of the fusions we identified were specific to RNA, with no evidence of corresponding genomic restructuring. Further, while the average total number of fusions in tumour and normal brain tissue samples is comparable, their overall fusion profiles vary significantly. Tumours have an over-representation of fusions occurring between coding genes, whereas fusions involving intergenic or non-coding regions comprised the vast majority of those in normals. Tumours were also more abundant in unique, sample-specific fusions compared to normals, though several fusions exhibited strong recurrence in the tumour type examined (diffuse intrinsic pontine glioma; DIPG) and were absent from both normal tissues and other cancers. Intriguingly, tumours also show broad up- or down-regulation of spliceosomal gene expression, which significantly correlates with fusion number (p=0.007). Our results show that RNA-specific fusions are abundant in both tumour and normal tissue and are associated with spliceosomal gene dysregulation. RNA-specific fusions should be considered as a potential mechanism that may contribute to cancer formation initiation and maintenance alongside more traditional structural events.
Open AccessFound in Transcription: Gene fusions arise through defects in RNA processing in the absence of chromosomal rearrangements
Recent advancements in high throughput sequencing analysis have enabled the characterization of cancer-driving fusions, improving our understanding of cancer development. Most fusion calling methods, however, examine either RNA or DNA information alone and are limited to a rigid definition of what constitutes a fusion. For this study we developed a pipeline that incorporates several fusion calling methods and considers both RNA and DNA to capture a more complete representation of the tumour fusion landscape. Interestingly, most of the fusions we identified were specific to RNA, with no evidence of corresponding genomic restructuring. Further, while the average total number of fusions in tumour and normal brain tissue samples is comparable, their overall fusion profiles vary significantly. Tumours have an over-representation of fusions occurring between coding genes, whereas fusions involving intergenic or non-coding regions comprised the vast majority of those in normals. Tumours were also more abundant in unique, sample-specific fusions compared to normals, though several fusions exhibited strong recurrence in the tumour type examined (diffuse intrinsic pontine glioma; DIPG) and were absent from both normal tissues and other cancers. Intriguingly, tumours also show broad up- or down-regulation of spliceosomal gene expression, which significantly correlates with fusion number (p=0.007). Our results show that RNA-specific fusions are abundant in both tumour and normal tissue and are associated with spliceosomal gene dysregulation. RNA-specific fusions should be considered as a potential mechanism that may contribute to cancer formation initiation and maintenance alongside more traditional structural events.
- 7 February 2018
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 30 (4) , e12579
A novel role of the corticotrophin‐releasing hormone regulating peptide, teneurin C‐terminal associated peptide 1, on glucose uptake into the brain
Teneurin C‐terminal associated peptide (TCAP) is an ancient paracrine signalling agent that evolved via lateral gene transfer from prokaryotes into an early metazoan ancestor. Although it bears structural similarity to corticotrophin‐releasing hormone (CRH), it inhibits the in vivo actions of CRH. The TCAPs are highly expressed in neurones, where they induce rapid cytoskeletal rearrangement and are neuroprotective. Because these processes are highly energy‐dependent, this suggests that TCAP has the potential to regulate glucose uptake because glucose is the primary energy substrate in brain, and neurones require a steady supply to meet the high metabolic demands of neuronal communication. Therefore, the objective of the present study was to assess the effect of TCAP‐mediated glucose uptake in the brain and in neuronal cell models. TCAP‐mediated 18F‐deoxyglucose (FDG) uptake into brain tissue was assessed in male wild‐type Wistar rats by functional positron emission tomography. TCAP‐1 increased FDG uptake by over 40% into cortical regions of the brain, demonstrating that TCAP‐1 can significantly enhance glucose supply. Importantly, a single nanomolar injection of TCAP‐1 increased brain glucose after 3 days and decreased blood glucose after 1 week. This is corroborated by a decreased serum concentration of insulin and an increased serum concentration of glucagon. In immortalised hypothalamic neurones, TCAP‐1 increased ATP production and enhanced glucose uptake by increasing glucose transporter recruitment to the plasma membrane likely via AKT and mitogen‐activated protein kinase/ERK phosphorylation events. Taken together, these data demonstrate that TCAP‐1 increases glucose metabolism in neurones, and may represent a peptide signalling agent that regulated glucose uptake before insulin and related peptides.
- 7 February 2018
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 30 (4) , e12579
A novel role of the corticotrophin‐releasing hormone regulating peptide, teneurin C‐terminal associated peptide 1, on glucose uptake into the brain
Teneurin C‐terminal associated peptide (TCAP) is an ancient paracrine signalling agent that evolved via lateral gene transfer from prokaryotes into an early metazoan ancestor. Although it bears structural similarity to corticotrophin‐releasing hormone (CRH), it inhibits the in vivo actions of CRH. The TCAPs are highly expressed in neurones, where they induce rapid cytoskeletal rearrangement and are neuroprotective. Because these processes are highly energy‐dependent, this suggests that TCAP has the potential to regulate glucose uptake because glucose is the primary energy substrate in brain, and neurones require a steady supply to meet the high metabolic demands of neuronal communication. Therefore, the objective of the present study was to assess the effect of TCAP‐mediated glucose uptake in the brain and in neuronal cell models. TCAP‐mediated 18F‐deoxyglucose (FDG) uptake into brain tissue was assessed in male wild‐type Wistar rats by functional positron emission tomography. TCAP‐1 increased FDG uptake by over 40% into cortical regions of the brain, demonstrating that TCAP‐1 can significantly enhance glucose supply. Importantly, a single nanomolar injection of TCAP‐1 increased brain glucose after 3 days and decreased blood glucose after 1 week. This is corroborated by a decreased serum concentration of insulin and an increased serum concentration of glucagon. In immortalised hypothalamic neurones, TCAP‐1 increased ATP production and enhanced glucose uptake by increasing glucose transporter recruitment to the plasma membrane likely via AKT and mitogen‐activated protein kinase/ERK phosphorylation events. Taken together, these data demonstrate that TCAP‐1 increases glucose metabolism in neurones, and may represent a peptide signalling agent that regulated glucose uptake before insulin and related peptides.